LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

Inicio・Lista de Acciones・Moderna Inc

Moderna Inc

Abierto

Sector Salud

53.65 -1.54

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

53.34

Máximo

55.56

Métricas clave
By Trading Economics
Ingresos	-104M -1.3B
Ventas	-167B 241M
P/B Media del Sector	35.86 104.138
BPA	-3.33
Margen de beneficio	-530.705
Empleados	5,600
EBITDA	-109M -1.2B

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 meses	+70.24 upside

Dividendos
By Dow Jones
Próximas Ganancias	7 nov 2024

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	522M 21B
Apertura anterior	55.19
Cierre anterior	53.65

Noticias sobre sentimiento de mercado

By Acuity

100%

373 / 390 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bullish Evidence

53.05 / 54.76 Soporte y Resistencia

Moderna Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

13 dic 2023, 13:16 UTC

Principales Movimientos del Mercado

Moderna Shares, Other Covid Vaccine Makers Hit by Warning From Pfizer

3 nov 2024, 23:34 UTC

Principales Noticias

Stocks Poised for Lower Open -- Barrons.com

28 oct 2024, 13:48 UTC

Ganancias

Moderna's Stock-Price Target Slashed. It's About Vaccines. -- Barrons.com

15 sept 2024, 07:00 UTC

Principales Noticias

World's Biggest Hedge Fund Sells Apple, Eli Lilly Stock, and Buys Microsoft, Moderna -- Barrons.com

12 sept 2024, 15:02 UTC

Principales Noticias

Moderna Cost Cuts Fail to Restore Investor Trust -- Heard on the Street -- WSJ

12 sept 2024, 10:00 UTC

Principales Noticias

Moderna Pulls Back on R&D and Delays Timeline for Profitability -- Barrons.com

6 sept 2024, 11:00 UTC

Principales Noticias

Pandemic Darling Moderna Needs a Reality Check -- Heard on the Street -- WSJ

3 sept 2024, 04:00 UTC

Principales Noticias

Novo, Amgen, Other Pharma Stocks Have Clinical Trials That Could Send Them Soaring -- Barrons.com

23 ago 2024, 18:38 UTC

Principales Noticias

The U.S. Is Bringing Back Free Covid Tests This Fall -- Barrons.com

2 ago 2024, 21:29 UTC

Principales Noticias

The Score: CrowdStrike, Apple, Intel and More Stocks That Defined the Week -- WSJ

1 ago 2024, 10:30 UTC

Principales Noticias

Moderna Cuts Revenue Guidance Amid Steeper Competition -- Barrons.com

3 jul 2024, 14:18 UTC

Adquisiciones, fusiones, absorciones

GSK Will Pay Up to $1.5 Billion for CureVac's mRNA Vaccines -- Barrons.com

30 may 2024, 19:45 UTC

Principales Noticias

Bird Flu Confirmed in Third Farmworker. It's the First Case With Respiratory Symptoms. -- Barrons.com

29 may 2024, 15:56 UTC

Ganancias

Adquisiciones, fusiones, absorciones

The Moderna Selloff Gains Steam. An Analyst Has a Few Theories Why. -- Barrons.com

10 may 2024, 20:11 UTC

Ganancias

These Stocks Moved the Most Today: Novavax, Akamai, Sweetgreen, Taiwan Semi, Moderna, Gen Digital, JFrog, SoundHound, and More -- Barrons.com

10 may 2024, 14:49 UTC

Ganancias

Acciones populares

Stocks to Watch Friday: TSMC, Novavax, Nvidia -- WSJ

2 may 2024, 13:46 UTC

Ganancias

Acciones populares

Stocks to Watch Thursday: Carvana, NIO, Qualcomm, Peloton -- WSJ

2 may 2024, 10:31 UTC

Ganancias

Moderna Puts Up Big Quarterly Beat; Could Shares Notch A Breakout? -- IBD

2 may 2024, 09:08 UTC

Acciones populares

Stocks to Watch Thursday: Shell, Novo Nordisk, Apple -- WSJ

28 feb 2024, 14:14 UTC

Ganancias

Novavax Stock Sinks as Revenue Misses Estimates in 'Transition Year' -- Barrons.com

22 feb 2024, 16:00 UTC

Principales Noticias

Moderna Is Pivoting From Covid and the Results Are on Their Way -- Heard on the Street -- WSJ

22 feb 2024, 12:40 UTC

Ganancias

Moderna Stock Jumps on Surprise Profit After Earnings Beat. What to Expect in 2024. -- Barrons.com

Comparación entre iguales

Cambio de precio

Moderna Inc Esperado

Precio Objetivo

By TipRanks

70.24% repunte

Estimación a 12 meses

Media 93 USD 70.24%

Máximo 238 USD

Mínimo 46 USD

De acuerdo con 19 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Moderna Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

19 ratings

Comprar

Mantener

Vender

De acuerdo con 19 analistas que ofrecen calificaciones bursátiles a para Moderna Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

53.05 / 54.76Soporte y Resistencia

All events are bullish.

All events are bearish.

Sentimiento

By Acuity

373 / 390 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Moderna Inc

Moderna, Inc. is a biotechnology company that is focused on creating a transformative medicines based on messenger ribonucleic acid (mRNA), to improve the lives of patients. The Company’s mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range of spectrum of diseases. It is developing vaccines and therapeutics for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with its strategic collaborators. The Company develops technologies that enable the development of mRNA medicines for diverse applications. It has created modalities, including prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, and systemic intracellular therapeutics. The Company develops technologies that enable the development of mRNA medicines.